Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.


Journal

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841

Informations de publication

Date de publication:
03 2020
Historique:
entrez: 29 4 2020
pubmed: 29 4 2020
medline: 8 10 2021
Statut: ppublish

Résumé

Previous study has shown a positive relationship between the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cholangiocarcinoma (CCA); however, their correlation with different anatomical sites of CCA (i.e. ICC and ECC) has not been revealed. This study aims to evaluate the association of HBV or HCV infection with CCA, including the intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), and to determine the roles of α-1 fetoprotein (AFP), CA19-9, and lymph node involvement in CCA with HBV infection. Relevant studies published between 2004 and 2016 were systematically searched and retrieved from PubMed, SpringerLink, and Science Direct using key terms such as "cholangiocarcinoma", "bile duct cancer", "extrahepatic cholangiocarcinoma", and "intrahepatic cholangiocarcinoma". The demographic, clinical, and laboratory data were extracted from the included studies, and the meta-analysis was performed using RevMan and STATA 11.0 software. A total of 13 studies with CCA matched the inclusion criteria in this meta-analysis, including 7,113 CCA patients and 24,763 controls. This meta-analysis showed that the HBV or HCV infections can significantly increase the risk of CCA, including ICC and ECC. In addition, the higher levels of AFP, lower levels of CA19-9, and lymph node involvement were detected in the CCA patients with HBV infection as compared to those without. The HBV and HCV infections significantly increased the risk of CCA, as well as ICC and ECC. The involvement of AFP, CA19-9, and lymph nodes may play an important role in the diagnosis of CCA.

Sections du résumé

BACKGROUND/AIMS
Previous study has shown a positive relationship between the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cholangiocarcinoma (CCA); however, their correlation with different anatomical sites of CCA (i.e. ICC and ECC) has not been revealed. This study aims to evaluate the association of HBV or HCV infection with CCA, including the intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), and to determine the roles of α-1 fetoprotein (AFP), CA19-9, and lymph node involvement in CCA with HBV infection.
MATERIALS AND METHODS
Relevant studies published between 2004 and 2016 were systematically searched and retrieved from PubMed, SpringerLink, and Science Direct using key terms such as "cholangiocarcinoma", "bile duct cancer", "extrahepatic cholangiocarcinoma", and "intrahepatic cholangiocarcinoma". The demographic, clinical, and laboratory data were extracted from the included studies, and the meta-analysis was performed using RevMan and STATA 11.0 software.
RESULTS
A total of 13 studies with CCA matched the inclusion criteria in this meta-analysis, including 7,113 CCA patients and 24,763 controls. This meta-analysis showed that the HBV or HCV infections can significantly increase the risk of CCA, including ICC and ECC. In addition, the higher levels of AFP, lower levels of CA19-9, and lymph node involvement were detected in the CCA patients with HBV infection as compared to those without.
CONCLUSION
The HBV and HCV infections significantly increased the risk of CCA, as well as ICC and ECC. The involvement of AFP, CA19-9, and lymph nodes may play an important role in the diagnosis of CCA.

Identifiants

pubmed: 32343237
doi: 10.5152/tjg.2020.19056
pmc: PMC7197930
doi:

Substances chimiques

AFP protein, human 0
Antigens, Tumor-Associated, Carbohydrate 0
alpha-Fetoproteins 0
carbohydrate antigen 199, human 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-256

Références

Asian Pac J Cancer Prev. 2010;11(4):985-8
pubmed: 21133611
Ann Oncol. 2013 Jun;24(6):1667-74
pubmed: 23378539
World J Gastroenterol. 2015 Jan 14;21(2):502-10
pubmed: 25593465
Ann Surg Oncol. 2011 May;18(5):1258-66
pubmed: 21207172
Stem Cell Rev. 2005;1(3):253-60
pubmed: 17142862
PLoS One. 2013 Jul 22;8(7):e69981
pubmed: 23894567
Hepatobiliary Surg Nutr. 2013 Oct;2(5):272-80
pubmed: 24570958
Ann Surg. 2008 Jul;248(1):84-96
pubmed: 18580211
Ann Surg. 2011 Nov;254(5):824-29; discussion 830
pubmed: 22042474
World J Gastroenterol. 2016 Mar 14;22(10):3038-51
pubmed: 26973400
Asian Pac J Cancer Prev. 2012;13(5):1963-9
pubmed: 22901155
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
World J Gastroenterol. 2014 Sep 21;20(35):12615-20
pubmed: 25253966
Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):682-687
pubmed: 27282820
Scand J Gastroenterol. 2011 Sep;46(9):1092-8
pubmed: 21692710
J Gastroenterol Hepatol. 2012 Oct;27(10):1561-8
pubmed: 22694354
Intern Med. 2014;53(7):651-4
pubmed: 24694471
Biomed Res Int. 2016;2016:3417976
pubmed: 27999794
Am J Gastroenterol. 2000 Jan;95(1):204-7
pubmed: 10638584
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Hepatology. 2001 Jun;33(6):1353-7
pubmed: 11391522
Cancer Cell Int. 2013 Oct 18;13(1):99
pubmed: 24139471
Eur J Cancer. 2010 Apr;46(6):1056-61
pubmed: 20202823
Int J Cancer. 2013 Oct 15;133(8):1867-75
pubmed: 23564396
World J Gastroenterol. 2011 Jan 14;17(2):249-53
pubmed: 21246000
J Hepatol. 2017 Jan;66(1):48-54
pubmed: 27592304
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Asia Pac J Clin Oncol. 2012 Mar;8(1):83-7
pubmed: 22369448
ANZ J Surg. 2018 Mar;88(3):212-217
pubmed: 27598539

Auteurs

Jie-Hui Tan (JH)

Division of Hepatobiliopancreatic Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Wan-Yan Zhou (WY)

Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Lei Zhou (L)

Division of Hepatobiliopancreatic Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Rong-Chang Cao (RC)

Division of Hepatobiliopancreatic Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Guo-Wei Zhang (GW)

Division of Hepatobiliopancreatic Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH